AMGN News
Amgen Inc.
$451.83
+$3.88(+0.87%)
73
Overall
80
Value
91
Tech
50
Quality
Market Cap
$241.81B
Volume
2.80M
52W Range
$288.00 - $450.98
Target Price
$403.35
AMGN news: the latest Amgen Inc. headlines, press releases and market updates, newest first.
Latest AMGN News
- RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)TipRanks Auto-Generated Intelligence Newsdesk · Oct 28, 2026
- Amgen Adds David Gibbs to Board of DirectorsTipRanks Auto-Generated Newsdesk · Oct 27, 2026
- Scotiabank Remains a Buy on Amgen (AMGN)TipRanks Auto-Generated Intelligence Newsdesk · Oct 26, 2026
- Goldman Sachs Remains a Buy on Amgen (AMGN)TipRanks Auto-Generated Intelligence Newsdesk · Oct 26, 2026
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Lexicon Pharmaceuticals (LXRX), Amgen (AMGN) and Demant (OtherWILLF)TipRanks Newsroom · Oct 26, 2026
- Amgen’s Bemarituzumab Trial Reaches Phase 3 Finish Line in Gastric CancerTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 23, 2026
- Citi Sticks to Its Hold Rating for Amgen (AMGN)TipRanks Auto-Generated Intelligence Newsdesk · Oct 21, 2026
- Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Qiagen (QGEN) and Teladoc (TDOC)TipRanks Newsroom · Oct 21, 2026
- Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Faeth Therapeutics (FTH)TipRanks Newsroom · Oct 16, 2026
- Amgen Fine-Tunes Evenity Delivery in New Phase 1 StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 13, 2026
- Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and United Therapeutics (UTHR)TipRanks Newsroom · Oct 12, 2026
- Bank of America Securities Remains a Sell on Amgen (AMGN)TipRanks Auto-Generated Intelligence Newsdesk · Oct 12, 2026
- Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 TrialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- Amgen’s AMG 513 Obesity Trial Reaches Phase 1 Completion, Adding a New Angle to the Weight-Loss Drug RaceTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
- Amgen’s Evolocumab Study Signals Quiet Efficiency Gains for Cholesterol FranchiseTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 2, 2026
- Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla GrowthTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 1, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMGN | $451.83 | +0.9% | 2.80M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |